Filing Flows › Crispr Therapeutics AG (CRSP) › Q1 2026
Crispr Therapeutics AG (CRSP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
Crispr Therapeutics AG (CRSP) reported revenue of $1.5M for the first quarter 2026 (Q1 2026), +69% from a year earlier and +69% from the quarter before.
Crispr Therapeutics AG, Q1 2026: revenue $1.5M (+69% year over year), net loss $123M, operating cash flow −$109M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | +69% | +69% |
| Operating profit | −$130M | — | — |
| Net earnings | −$123M | — | — |
| Operating cash flow | −$109M | — | — |
What changed
Revenue was $1.5M in Q1 2026, up 69% year over year and up 69% from the previous quarter. Collaboration Revenue was the largest line at 69% of revenue. Grant declined 47%.
Operating costs exceeded revenue by $130.2M, an operating margin of -8933.3%. Total costs fell 12% while revenue rose 69%. The quarter ended with a net loss of $122.9M, narrower than the previous quarter's $130.6M loss.
Operating cash flow was −$108.9M. Non-cash charges added back $4.3M of depreciation and amortization and $16.3M of share-based compensation. Working capital and other items used $6.6M. Capital expenditures of $504K exceeded it, leaving free cash flow of −$109.4M.
Questions
What was Crispr Therapeutics AG's revenue in the first quarter 2026?
Crispr Therapeutics AG (CRSP) reported revenue of $1.5M for the first quarter 2026 (Q1 2026), +69% from a year earlier and +69% from the quarter before.